The U.S. Food and Drug Administration said it approved Boston-based Vertex Pharmaceuticals' Journavx for short-term pain that ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than two decades.The<a class="excerpt-read-more" href=" More ...
Plus, NBC News spoke to trans service members about their thoughts on President Trump's executive order banning trans people from enlisting and serving in the military.
In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
Truist Financial analyst Joon Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s shares closed ...